UK – ABPI details Brexit plans at PIPA conference

The Association of the British Pharmaceutical Industry (ABPI) announced its latest Brexit contingency plans at the PIPA Conference 2019, stating that it still firmly believes that leaving European Union with deal in place is best way to minimise potential disruption.

The organisation pleads that a ‘no-deal’ scenario must be avoided, and that it has been engaging with the government in the form of meetings with ministers and advisers, as well as seeking confirmation from the Medicines and Healthcare products Regulatory Agency (MHRA) that it is seeking European Medicines Agency (EMA) regulatory participation.

The ABPI also stressed that it wants as close regulatory alignment with the EMA as possible, and reminded that the branded medicines bill will not grow by more than 2% in any of the next five years – a pro-innovation deal that is “particularly” important as the UK leaves the EU.

The scheme – the Voluntary Scheme ‘VPAS’ – includes a commitment from NHS England to increase uptake of new medicines for the five highest health gain categories in line with the top performing countries in the world…